3rd Annual PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

A STRATEGIC-LEVEL FORUM WITH THE WIDEST RANGE OF DRUG DELIVERY TECHNOLOGIES

OCTOBER 10 - 11, 2013 THE FAIRMONT COPLEY PLAZA HOTEL, BOSTON, MA

Keynote Fireside Chat with Robert Langer, PhD
David H. Koch Institute Professor
MIT

Disruptive Keynote Georges Whitesides, PhD
Professor of Chemistry
Harvard University

Chaired by Barbara Lueckel, PhD
Global Business Development Director
Roche

Industry Keynote John Ludwig, PhD
SVP, BioTherapeutics Pharmaceutical Sciences
Pfizer

CONFERENCE HIGHLIGHTS

THURSDAY, OCTOBER 10, 2013
✓ Fireside Chat with Dr. Robert Langer, MIT
✓ Industry Keynote: The Future of R&D on Drug Delivery with Dr. John Ludwig, Pfizer
✓ Delivery of Biologics Panel
✓ Partnering Viewpoint Panel: Pharma and Drug Delivery Perspectives on Collaborating
✓ Drug Delivery Presentations in Two Tracks: Formulation and Device Technologies
✓ Networking Reception & Partnering Meetings

FRIDAY, OCTOBER 11, 2013
✓ Disruptive Keynote: Disrupting the Future of Healthcare with Drug Delivery
✓ Nanomedicine: Why Should Pharma Invest?
✓ Third Annual Company Spotlights
✓ Luncheon Sessions/Round Table Topics
✓ DDS Technology Soapbox@PODD
✓ Funding Drug Delivery
✓ Closing the Innovation Gap Perception

TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
OVERVIEW

The Conference Forum is delighted to present the 3rd Annual PODD, Partnership Opportunities in Drug Delivery event. This annual Boston-based conference is designed with three purposes:

1. To present a strategic level program for pharma and biotech business development professionals with a thorough overview of the latest drug delivery technologies available, along with an update on deals and opportunities to improve therapies and extend the life cycle of a drug.

2. To provide drug delivery and specialty pharmas with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.

3. To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones.

The 3rd annual event is chaired by Barbara Lueckel, PhD, Global Business Development Director, Roche and keynoted by Robert Langer, PhD, David H. Koch Institute Professor, MIT and George M. Whitesides, PhD, Woodford L. and Ann A. Flowers University Professor, Harvard University and Founding Core Faculty Member, Wyss Institute. Our dedicated PODD website pages will bring you through the 2012 experience to give you a sense of the standard of quality for our 2013 event.

The ultimate goal for PODD is to foster a meeting place that inspires innovation and advancement of drug development and delivery as well as providing support for the leaders behind the movement.

SPEAKING FACULTY

Noubar Afeyan, PhD
Managing Partner & CEO
Flagship Ventures

PJ Anand
Founder, President & CEO
Acyone Lifesciences, Inc.

Jessica Ballinger
Senior Director, Protein Pharmaceutical Development
Biogen Idec

Jonathan R. Behr, PhD
Vice President of New Ventures
Enlight Biosciences

Greg I. Berk, MD
Chief Medical Officer
BIND Therapeutics

Sangeeta N. Bhatia, MD, PhD
Professor, Koch Institute
MIT

Kevin Bitterman, PhD
Principal
Polaris Partners

Werner Cautreels, PhD
CEO
Selecta Biosciences

Faz Chowdhury, MD
CEO
Nemaura Pharma Limited

Weiguo Dai, PhD
Scientific Director, Janssen Fellow
Janssen Research and Development

Mariana Dimitrova, PhD
Director Formulation and Process Development, Protein Pharmaceutical Development
Biogen Idec

Omid Farokhzad, MD
Associate Professor of Anaesthesia, Harvard Medical School and Director of the Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital

Brian M. Gallagher, Jr., PhD
Partner
SR One Ltd.

Mary Gardner, MBA
Director, Technology Assessment
Hospira

Baruch Harris, PhD
Vice President, Strategy & Operations
Fidelity Biosciences

Michael D. Hooven
President & CEO
Enable Injections, LLC
TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
8:00 am
Breakfast, Registration & Partnering Meetings

8:45 am
Chair’s Opening Remarks
Barbara Lueckel, PhD
Global Business Development Director, Roche

9:00 am
Fireside Chat with:
Robert Langer, PhD
David H. Koch Institute Professor, MIT
In a fireside chat with one of the most influential and renowned scientists in the industry, we address:

- What are some examples of really important problems in drug delivery that not enough people are working on and what should have more attention?
- What makes the difference between success and failure of drug delivery companies?
- With more than 30 startups – other than luck, what’s the view on the key things that make the difference between success and failure?
- Why have alternative drug delivery (nasal, inhalation, active and chemically enhanced transdermal, pulsatile etc) not been more successful commercially despite the 20+ years we have been doing research in this area?
- Thoughts on the funding environment for drug delivery startups
- Strategies for dealing with the challenges of the funding environment
- If you had to re-look at DDS, what would you do differently and where do you see things going given the current healthcare climate?

9:50 am
Featured Guest Speaker: The Future of BioTherapeutics R&D
In this presentation John Ludwig, SVP BioTherapeutics Pharmaceutical Sciences, Pfizer will share his thoughts on the latest trends in pharmaceutical R&D. Topics addressed:

- The growing role of Biotherapeutics: industry trends and Pfizer’s portfolio transformation in the past decade
- The importance of drug delivery technologies for medical and commercial product differentiation based on customer insights
- The growing cost of product development demands; different and more creative ways of collaboration between Pharma and technology developers: open innovation; early engagement; cost- and resource-sharing ; non-competitive Consortiums
- How will the future of R&D impact the drug delivery sector?

John Ludwig, PhD
SVP, BioTherapeutics Pharmaceutical Sciences, Pfizer

10:30 am
Networking Break & Partnering Meetings

11:15 am
Delivery of Biologics Panel: New Paradigms, Formulation Challenges & Partnering Needs

- Role of drug delivery and when to introduce into the development pipeline
- What are the key formulation and delivery needs of biologics?
- Which DDS technologies are in high demand to meet biologics delivery challenges?
- How do biologics developers view novel DDS and what are they looking for in a partner?

Moderator:
Julia Rashba-Step, PhD
Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

Panelists:
Jessica Ballinger
Senior Director, Protein Formulation Development, Biogen Idec
Weiguo Dai, PhD
Scientific Director, Janssen Fellow, Janssen Research and Development
Tomas Landh, PhD
Director, Strategy & Sourcing, Diabetes Research Unit, Novo Nordisk
Andy Lewis, PhD
Director, Novel Formulation Technologies, Ipsen
Anand Subramony, PhD
Principal Fellow & Head, Novel Delivery Technologies & Therapeutics (NDT), Novartis Institutes for Biomedical Research
12:00 noon
Partnering Viewpoint Panel: Pharma and Drug Delivery Perspectives on Collaborating

- Role of DDS in pharma pipeline; when and how is DDS technology sourced?
- What criteria does pharma use when evaluating a DDS technology or provider?
- What are drug delivery companies looking for in a pharmaceutical partner?
- What are the key challenges in executing and maintaining a successful partnership?
- Today’s partnership agreement – typical terms and structure
- Importance of knowledge sharing and collaboration in the development of next-generation drug delivery excipients, materials and manufacturing processes

Moderator:
Mark Wilson, PhD, MBA
Director, Collaboration Management, Europe, Platform Science and Technology, GlaxoSmithKline Pharmaceuticals

Panelists:
Mary Gardner, MBA
Director, Technology Assessment, Hospira

Richard W. Korsmeyer, PhD
Senior Research Fellow and Head of External Technology & Collaborations, PTx PS Technology and Innovation, Pfizer

Sesha Neervannan, PhD
Vice President, Pharmaceutical Development, Allergan, Inc.

Fernando Salles, PhD
Executive Director, Strategic Licensing & Acquisitions Lead Ophthalmics and Drug Delivery Technologies, External Scientific Affairs, Merck

Kevin Sooben, PhD
Team Manager, Pharmaceutical R&D, AstraZeneca

12:45 pm
Lunch

2:00 pm - 6:00 pm
Afternoon Drug Delivery Technology Presentations in 2 Tracks

Attendees can choose between sessions in the following two simultaneous technology tracks:

**TRACK ONE** -
Drug Delivery Formulation Technologies

Chaired by:
Avinash Thombre, PhD
Research Fellow, Pfizer

Approximately 12-14 companies present formulation technologies that can enhance, enable, or facilitate the delivery of a drug. Examples: nanoparticles, polymers/biodegradable materials, liposomes, tablets/capsules/liquids, conjugates, microparticles, lipids/emulsions, excipients, orally-disintegrating tablets/films, etc.

- Aptalis
- Emultech
- Enteris Pharma Inc.
- GSK
- Kala Pharmaceuticals
- Nanomi BV
- NanoVelos
- Octoplus
- Phosphorex
- Xeris Pharmaceuticals

**TRACK TWO** -
Drug Delivery Device Technologies

Chaired by:
Paul Jansen
Global Head, Medical Devices, Sanofi-Aventis

Approximately 12-14 companies present needle-free delivery devices, auto injectors, pen injectors, powder injection devices, microneedle systems, inhalation devices, nasal delivery devices, non-biodegradable implants or similar, transdermal patches, patch pumps and other wearable drug administration systems, etc.

- 3M
- Battelle
- Enable Injections
- Impel NeuroPharma
- LyoGo
- Mitsubishi Gas Chemical
- Novozymes
- Novo Cervical
- Renishaw
- Transdermal Delivery Solutions
- Unilife
- West Pharmaceutical
- Nemura Pharma Ltd.

3:45 pm - 4:00 pm
Break

6:00 pm
Networking Reception & Partnering Meetings
DAY TWO - FRIDAY, OCTOBER 11, 2013

8:00 am
Breakfast & Partnering Meetings

8:30 am
Chair's Welcome
Barbara Lueckel, PhD
Global Business Development Director, Roche

8:45 am
Disruptive Keynote: Disrupting the Future of Healthcare with Drug Delivery

- How does drug delivery fit into healthcare cost-reduction and public health/point of care models of healthcare?
- What is the role of drug delivery (or delivery of other substances, such as vitamins) in the developing world?
- What is the role of drug delivery in telemedicine, and integrating healthcare with the cloud?
- Discuss “smart” delivery: delivery coupled to sensing
- What about drug delivery, drug efficacy, and clinical trials?

George M. Whitesides, PhD
Woodford L. and Ann A. Flowers University Professor, Harvard University and Founding Core Faculty Member, Wyss Institute

9:30 am
Nanomedicine: Why Should Pharma be Investing in this Area?

- Is nanomedicine now better positioned to make an impact on patients’ lives?
- How to assess the commercial aspects of nanoparticle development
- How is nanomedicine expected to potentially transform medicine?
- What is the role of nanomedicine in the era of genomics?
- Barriers and challenges – safety/nanotoxicology, manufacturing issues
- What are the unique aspects of the nanomedicine business model?

Moderator:
Omid Farokhzad, MD
Associate Professor, Harvard Medical School

Panelists:
Greg I. Berk, MD
CMO, BIND Therapeutics
Sangeeta N. Bhatia, MD, PhD
HHMI and Professor, Koch Institute at MIT
Werner Cautreels, PhD
CEO, Selecta Biosciences
Mark Iwicki
CEO, Blend Therapeutics
Chuck Wilson, PhD
VP & Global Head of Strategic Alliances, Novartis Institute of BioMedical Research

10:15 am
Networking Break & Partnering Meetings

11:00 am
Third Annual Company Spotlights – Part I

In this session, we highlight three companies that discuss their partnering philosophy, current needs and scouting interests as related to drug delivery.

- Novo Nordisk
- Pfizer
- Roche

12:00 noon
Third Annual Company Spotlights – Part II

In this session, we highlight three companies that discuss their role in advancing drug delivery.

Mark A. Tomai, PhD
Head of TLR and MTS Business Development, 3M Drug Delivery Systems

2. Patheon

3. Innovations in Transdermal Drug Delivery
Kenneth Kirby
President & CEO, Transdermal Delivery Solutions Corporation

1:00 pm
Luncheon Sessions

Attendees have a choice to be part of our open networking luncheon, conduct partnering meetings or join a round table discussion dedicated to a specific topic.

Each of the topic round tables has a dedicated moderator with expertise in the particular area.
Round Table Topics

1. Drug Delivery out of Academia
   Baruch Harris, PhD
   Venture Partner, Fidelity Biosciences

2. Delivering High Concentrations Formulations
   Mariana Dimitrova, PhD
   Director Formulation and Process Development, Protein Pharmaceutical Development, Biogen Idec

3. Raising Capital in Drug Delivery
   Jonathan R. Behr, PhD
   Vice President, New Ventures, Enlight Biosciences

4. Disruptive Technologies
   A. Lee Shorter, PhD
   Director, Disruptive Technology Seeker, GSK

5. Drug Targeting
   Anand Subramony, PhD
   Principal Fellow & Head, Novel Delivery Technologies & Therapeutics (NDT), Novartis Institutes for Biomedical Research

6. Device Challenges for High Volume Pharmaceuticals
   Atul Patel
   Director, Technical Development (Devices), Biogen Idec

2:15 pm
DDS Technology Soapbox@PODD
This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

If you are interested in presenting on the Soapbox, please let us know at service@theconferenceforum.org.

3:00 pm
Soapbox Partnering Meetings/Networking Break

3:20 pm
Funding Drug Delivery
- State of the market
- Who is getting funded and why?
- Alternative sources of funding
- Traditional vs non-traditional

Moderator:
PJ Anand
Founder, President & CEO, Alcyone Lifesciences, Inc.

Panelists:
Noubar Afeyan, PhD
Managing Partner & CEO, Flagship Ventures
Jonathan R. Behr, PhD
Vice President of New Ventures, Enlight Biosciences
Kevin Bitterman, PhD
Principal, Polaris Partners
Brian M. Gallagher, Jr, PhD
Partner, SR One Ltd.
Baruch Harris, PhD
Venture Partner, Fidelity Biosciences

4:00 pm
Closing the Innovation Gap Perception between Pharma and Drug Delivery
- What is perceived as innovative or novel; both internally and externally? Is it just “new” or “different” enough?
- What is big pharma looking for in terms of new “innovations”?
  - Formulations
  - Continuous Manufacturing
- How can companies collaborate more successfully to bring new innovations to market?
- Other industries are constantly innovating – what can we learn from them?
- What criteria is used to determine which innovation(s) warrant investment?

Moderator:
Sven Stegemann, PhD
President, Geriatric Medicine Society

Panelists:
Mak Jawadekar
formerly Director, Portfolio Management & Analytics, Pfizer, Inc. and Scientific Board Member, Oncobiologics and Livwell Therapeutics
Leon Sandler
Executive Director, MIT Deshpande Center for Technological Innovation
A. Lee Shorter, PhD
Director, Disruptive Technology Seeker, GSK
Morten Sogaard, PhD
Executive Director, Head, Biotechnology & Precision Medicine, External R&D Innovation, Pfizer, Inc.

5:00 pm
Conference Concludes
3RD ANNUAL PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

VENUE / REGISTRATION / SPONSORS

HOTEL INFORMATION

The Fairmont Copley Plaza Hotel
138 St. James Avenue
Boston, MA 02116
617-267-5300
www.fairmont.com/copley-plaza-boston/

For reservations, call 800-441-1414 or 617-267-5300 and ask for the PODD group rate.

REGISTRATION & PRICING

Early Early Bird - before March 1, 2013 $1,595
Early Bird - before August 2, 2013 $1,795
Standard - after August 2, 2013 $1,995

The conference fee includes the program, morning coffee/tea, reception, luncheons, and conference documentation.

Discount Programs

Group Registration – Receive a 10% discount off each registration when two or more colleagues from the same company register online.

Large group discounts available.

Please contact Service@theconferenceforum.org or call 646-350-2580 for any questions on discount rates.

Payment Policy

Payment must be received in full by the event date. All discounts will be applied to the Conference-Only fee (excluding add-ons), cannot be combined with any other offer, and must be paid in full at the time of conference.

Substitution and Cancellation Policy

If you are unable to attend and would like to register a substitute, please email Service@theconferenceforum.org. Please ask your substitute to provide identification on-site.

If you need to cancel your registration, please note the following policies based on the start date of the event:

Ten or more business days prior: A full refund less the administration fee of $295, or a pass to another event valid for two years from the date of issue.

Less than ten business days prior: A pass to a future event for either yourself or a colleague from the same company valid for two years from the date of issue.

To cancel and receive a refund or pass, please email Service@theconferenceforum.org or call 646-350-2580.

EXECUTIVE SPONSORS

3M

Opsona

TRANSDERMAL DELIVERY SOLUTIONS

TECHNOLOGY SPONSORS

APATIS

Ballute

enteris

Impel

kala

nanomix

Nemaurx

Nitram Pharma

phosphorex

REISHAW

West

XERIS

SOAP BOX SPONSOR / EXHIBITORS

AMPEX TECHNOLOGIES

ITS Orthomem Thermo-Systems

PolyScience, Inc.

xmedica

SUPPORTING PARTNERS

MICHELL

SOUTH DAKOTA BIOTECH ASSOCIATION

WIB

PARTICIPATING INVESTORS

enlight Biosciences

FIDELITY BIO SCIENCES

FLAGSHIP VENTURES

POLARIS

SR·one

MEDIA PARTNERS

BioCentury

Drug Development Today

Larta Institute

PharmaVOICE

TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580